- Correction
- Open access
- Published:
Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
Orphanet Journal of Rare Diseases volume 19, Article number: 131 (2024)
The Original Article was published on 25 February 2024
Correction to: Orphanet Journal of Rare Diseases (2024) 19:86
Following publication of the original article [1], we have been notified that there should be a disclaimer published in the Acknowledgement note.
Acknowledgement note now is:
The authors would like to thank Sandra Retzky and Dionna Green for their input on this research project.
Acknowledgement note should be:
The authors would like to thank Sandra Retzky and Dionna Green for their input on this research project.
This manuscript reflects the views of the authors and should not be construed to represent FDA’s and the Department of Health and Human Services (HHS)’s views or policies.
References
Mease et al. Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development. Orphanet J Rare Dis. 2024;19:86. https://0-doi-org.brum.beds.ac.uk/10.1186/s13023-024-03097-x.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://0-doi-org.brum.beds.ac.uk/10.1186/s13023-024-03097-x.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Mease, C., Miller, K.L., Fermaglich, L.J. et al. Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development. Orphanet J Rare Dis 19, 131 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s13023-024-03136-7
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13023-024-03136-7